The appeal of a daily pill is easy to understand. It fits into a routine, feels manageable and avoids the discomfort of injections.
For many people using weight-loss medication, tablets represent a simpler path forward. Now, researchers say one of the pill’s lesser-known ingredients deserves closer attention.
Scientists at Adelaide University have examined salcaprozate sodium, or SNAC, a compound used in the tablet versions of Wegovy and Ozempic.
While semaglutide is the active drug, SNAC plays a crucial role by protecting it in the stomach and helping it enter the bloodstream.
Also read: Pharmacist warns about overlapping vitamin intake
In a 21-day animal study led by PhD candidate Amin Ariaee and Senior Research Fellow Dr. Paul Joyce, repeated exposure to SNAC was linked to several biological changes.
What changed
Researchers observed:
- Fewer beneficial gut bacteria involved in fibre digestion
- Reduced levels of short-chain fatty acids that support gut health
- Higher markers of inflammation in the blood
- Increased liver weight
- Lower levels of a brain-related protein linked to cognitive decline
The study does not show that SNAC causes harm in humans. However, the findings suggest the compound may influence the body beyond simply aiding drug absorption.
Why it matters
As oral versions of semaglutide become more widely available, daily exposure to SNAC could increase.
Also read: These bodily symptoms may be linked to stress
With obesity rates high globally and prescriptions rising, researchers argue that understanding every component of these medications is essential.
The team emphasizes that further long-term human studies are needed before drawing conclusions.
Source: Science Daily and Science Direct
Also read: New study links high tyrosine levels to shorter lifespan in men
Also read: She took collagen daily for a year – see her before-and-after photos